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Authors. Published by Elsevier Ltd. on behalf of IBRO. This
is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Key words: Alzheimer’s disease, b-amyloid, butyryl-
cholinesterase, 5XFAD mouse, butyrylcholinesterase-knock-
out, cholinergic system.
INTRODUCTION
The ‘‘amyloid hypothesis’’ suggests that this abnormally
folded b-amyloid (Ab) protein may be one of the
important pathological contributors to neuronal loss in
Alzheimer’s disease (AD) (Lorenzen et al., 2010;
Masters and Selkoe, 2012). A number of factors con-
tribute to Ab accumulation, including genetic mutations
in the amyloid precursor protein and cofactors that are
involved in its processing, such as presenilins (Blennow
et al., 2006; Querfurth and LaFerla, 2010). In addition,
butyrylcholinesterase (BChE), a serine hydrolase that
has a number of functions in health and disease
(Mesulam et al., 2002; Giacobini, 2003; Darvesh et al.,http://dx.doi.org/10.1016/j.neuroscience.2015.04.039
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4242003; Greig et al., 2008), may also be involved in AD
pathology. In AD, both BChE and acetylcholinesterase
(AChE), but particularly BChE, become associated with
Ab plaques, neuroﬁbrillary tangles and cerebral amyloid
angiopathy (Mesulam and Geula, 1994; Geula and
Mesulam, 1995; Guillozet et al., 1997). In fact, while
AChE levels in the AD brain are signiﬁcantly reduced,
BChE levels have been found to remain the same or
increase (Perry et al., 1978; Atack et al., 1987; Darvesh
et al., 2010). In addition, it has been found that BChE is
primarily associated with the ‘‘malignant’’, ﬁbrillar Ab pla-
ques characteristic of AD but not the ‘‘benign’’, non-ﬁbril-
lar plaques which are often found in individuals without
dementia (Mesulam and Geula, 1994). This association
has led some to suggest that BChE may be involved in
Ab transformation from the ‘‘benign’’, non-ﬁbrillar form to
the ‘‘malignant’’ ﬁbrillar form characteristic of AD
(Guillozet et al., 1997) but a mechanism for this process
has not been elucidated. In contrast, other in vitro studies
have suggested that BChE may decrease Ab ﬁbril forma-
tion (Diamant et al., 2006). Consequently, the role of
BChE in plaque deposition remains unclear.
A number of polymorphisms in the BCHE gene have
been described, the most common being the BCHE-K
variant (Bartels et al., 1992), where there is an A539T sub-
stitution that is found in approximately one-third of the
human population and exhibits a 30% reduction in the
molecular concentration of BChE (Bartels et al., 1992).
Investigations of this BCHE variant have observed that its
presence pre-empts progression of AD (Sandbrink et al.,
1998; O’Brien et al., 2003). However, other studies have
suggested that this variant is associated with AD (Tilley
et al., 1999; Wiebusch et al., 1999; Lehmann et al., 2000;
Lehmann et al., 2001; McIlroy et al., 2000) and still others
have observed no association of BCHE-K variant with AD
(Hiltunen et al., 1998; Kehoe et al., 1998; Singleton et al.,
1998; Grubber et al., 1999; Ki et al., 1999; Yamamoto
et al., 1999). This suggests that the role(s) of BChE in AD
may involve other components of the disease and requires
further scrutiny. This notion is supported by a recent gen-
ome-wide association study, using 18F ﬂorbetapir PET
imaging data to assess in vivo Ab levels in the brains of
555 patients of the Alzheimer Disease Neuroimaging
Initiative. This study has demonstrated the BCHE gene is
one of few identiﬁed, along with that for ApoE, that is asso-
ciated with AD (Ramanan et al., 2014). This observation
represents the largest known eﬀect of the BCHE gene on
AD-related phenotype. The study concluded that BChE-ons.org/licenses/by-nc-nd/4.0/).
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BCHE locus associated with Ab burden, may provide a
means for BChE-modulating agents to alter disease pro-
gression (Ramanan et al., 2014). Further studies of the
interaction of BChEandAb in an animalmodelmay provide
insights into AD pathogenesis.
The B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)
6799Vas/Mmjax mouse overexpresses mutant human
APP695 with Swedish (K670N/M671L), Florida (I716V)
and London (V717I) Familial Alzheimer’s disease (FAD)
mutations along with human presenilin-1 harboring two
FAD mutations, M146L and L286V (Oakley et al., 2006).
This 5XFAD mouse is a useful model for studying Ab pla-
ques as it rapidly develops this pathology, characteristi-
cally similar to plaques in human AD brains (Oakley
et al., 2006). Accumulation of Ab42 begins as early as
1.5 months of age in the 5XFAD mouse, increases with
age and female mice show higher Ab42 levels than males
(Oakley et al., 2006).
The B6.129S1-Bchetn1Loc/J mutant mouse is a
BChE-knockout (BChE-KO) model that does not
produce any BChE enzyme (Li et al., 2006) and is a useful
model for studying the functions of this enzyme (Duysen
et al., 2007). In this strain, the targeting vector contains
an 891-bp deletion of the BCHE gene, removing the splice
junction between intron 1 and exon 2. This deletion
includes the entire signal peptide of which the translation
start site and the ﬁrst 102 amino acids of the mature
BChE protein are also removed (Li et al., 2006).
Homozygous BChE-KO mice have a complete lack of
BChE in all tissues and plasma with no apparent anoma-
lies in physical appearance or cognition (Li et al., 2008).
To address the unresolved role of BChE in Ab plaque
accumulation, the 5XFAD mouse was cross-bred with a
BChE-KO strain producing a new 5XFAD/BChE-KO
strain, that accumulates Ab plaques but does not
synthesize BChE. Since in human AD (Corder et al.,
2004; Barnes et al., 2005; Vest and Pike, 2013; Li and
Singh, 2014; Mielke et al., 2014) and in AD mouse models
(Oakley et al., 2006; Hirata-Fukae et al., 2008; Carroll
et al., 2010) females have higher Ab plaque burden,
females and males were analyzed separately in the
present study. Comparison of 5XFAD/BChE-KO with
age-matched 5XFAD mice revealed diminished ﬁbrillar
Ab plaque burden, especially in males.Table 1. Primers used for mouse genotyping (Jackson laboratories)
BCHE mutant
(oIMR7415)
GCCAGAGGCCACTTGTGTAG
BCHE common
(oIMR8093)
CATGGAAAAGAGGAGGATGG
BCHE wild-type
(oIMR8094)
TTCCACTTGGAAGAGAAACACA
APP forward ACAGAATTCGCCCCGGCCTGGTAC
APP reverse TAAGCTTGGCACGGCTGTCCAAGGA
PSEN1 forward
(oIMR1644)
AATAGAGAACGGCAGGAGCA
PSEN1 reverse
(oIMR1645)
GCCATGAGGGCACTAATCATEXPERIMENTAL PROCEDURES
Animals
Formal approval to conduct these experiments was
obtained from the Dalhousie University Committee on
Laboratory Animals. Female wild-type (WT; C57BL/
6J  SJL/J F1; The Jackson Laboratories, Stock #
100012), male transgenic hemizygous 5XFAD (B6SJL-
Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax;
Mutant Mouse Regional Resource Center, 034840-JAX)
and heterozygous butyrylcholinesterase (B6.129S1-
Bchetm1Loc/J; The Jackson Laboratories, Stock #
008087), referred to here as BChE-het mice, were
purchased. Mice were housed in same-sex groups of 1–
5, within polyethylene cages, containing a wood-chipbedding and covered by a metal cage top and micro-
isolator ﬁlter. Food (Purina rodent chow, #5001) and tap
water were available ad libitum. Animals were kept in
normal light/dark cycle.
It has been noted that female hemizygous 5XFAD
mice are not suitable mothers due to the detrimental
eﬀects caused by the accumulation of Ab.
Consequently, for the generation of 5XFAD and 5XFAD/
BChE-KO oﬀspring, female 5XFAD or 5XFAD/BChE-KO
mice were not used for breeding. Hemizygous 5XFAD
mice, used for breeding and subsequent experiments,
were produced from pairs of WT female mice bred with
5XFAD male mice. Homozygous BChE-knockout
(BChE-KO) mice were produced from BChE-het males
and females. A three generation breeding scheme was
used to produce the desired transgenic hemizygous
5XFAD strain that were homozygous BChE-knockout
(5XFAD/BChE-KO). Hemizygous male 5XFAD mice
were bred with pairs of BChE-KO females to produce
5XFAD/BChE-het mice. Male 5XFAD/BChE-het mice
were bred with female BChE-KO mice to produce
5XFAD/BChE-KO mice. To maintain the strain and
produce mice for subsequent experiments 5XFAD/
BChE-KO males were bred with BChE-KO females.
The number of animals used for these experiments
were as follows; 5XFAD (3-month-old males n= 7,
6-month-old males n= 5, 3-month-old females n= 9,
6-month-old females n= 6) and 5XFAD/BChE-KO
(3-month-old males n= 10, 6-month-old males n= 4,
3-month-old females n= 6, 6-month-old females n= 6).
Genotyping
An ear punch was used to identify mice and collect a skin
sample for genotyping. For DNA isolation, 80 ll of
0.025 M sodium hydroxide and 0.2 mM EDTA disodium
dihydrate was added to skin samples and was
incubated at 98 C for 1 h with periodic vortexing to
digest tissue. Following tissue digestion, 80 ll of a
neutralization solution containing 40 mM Tris HCl at pH
5.5 was added, vortexed and centrifuged at 4000 rpm
for 3 min (Truett et al., 2000). The supernatant was
removed and saved for polymerase chain reaction
(PCR). Each mouse was genotyped for APP, PSEN1
and BCHE genes. To each PCR tube was added 2.5 ll
PCR buﬀer (0.2 M Tris–HCl and 0.5 M KCl pH 8.4),
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0.75 ll MgCl2, 0.625 ll primers (see Table 1 for primer
sequences purchased from Sigma–Aldrich, St. Louis,
MO, USA), 5 ll DNA isolate, 0.1 ll Taq (Invitrogen;
10342–020) and 14.9 ll ultrapure dH2O. PCR samples
were ampliﬁed on a BIORAD C1000 Touch thermal
cycler. For BCHE the following protocol was used: 94 C
2 min, 34 times (94 C for 30 s, 59 C for 30 s, 72 C for
1 min), 4 C for 5 min. For APP and PSEN1, 94 C
2 min, 34 times (94 C for 30 s, 65 C for 30 s, 72 C for
1 min), 4 C for 5 min. PCR products were run on a 2%
agarose gel made with TAE buﬀer, containing 0.04 M
Tris–acetate and 0.001 M EDTA, with SYBR safe DNA
gel stain (Invitrogen; S33102, 1:10,000). Gels were run
for 30 min and visualized on a Typhoon 9410 Molecular
Imager (GE Healthcare).Brain preparation
Mice were euthanized by a lethal intraperitoneal sodium
pentobarbital injection, perfused transcardially with
saline (25 mL, 0.9% NaCl, 0.1% NaNO3) and 50 mL of
4% formaldehyde in 0.1 M phosphate buﬀer (PB, pH
7.4), the brains removed and post-ﬁxed for 1.5 h. Brains
were then immersed in 30% sucrose in PB with 0.05%
sodium azide and stored at 4 C until used. Brains were
frozen with dry ice and cut into 40 lm serial coronal
sections on a Leica SM2000R microtome with
Physitemp freezing stage and BFS-30TC controller.
Sections were stored at 4 C in PB with 0.08% sodium
azide until used for analysis of BChE and AChE activity
with histochemistry, ﬁbrillar Ab with thioﬂavin-S (Th-S)
histoﬂuorescence and Ab using immunohistochemistry.Cholinesterase histochemistry
Cholinesterase staining was performed using a modiﬁed
(Darvesh et al., 2012) Karnovsky-Roots method
(Karnovsky and Roots, 1964). All reagents were pur-
chased from Sigma–Aldrich (St. Louis, MO, USA). The
substrate used for visualization of BChE activity was
butyrylthiocholine, where AChE activity was inhibited by
BW 284 C 51 (1,5-bis [4-allyl dimethylammonium phenyl]
pentan-3-one dibromide) at a ﬁnal concentration of
0.01 mM. Brieﬂy, tissue sections were rinsed in 0.1 M of
maleate buﬀer (pH 7.4) for 30 min; they were then incu-
bated for 2 h in 0.1 M maleate buﬀer (pH 6.8) containing
0.5 mM sodium citrate, 0.47 mM cupric sulfate, 0.05 mM
potassium ferricyanide, 0.8 mM butyrylthiocholine iodide
and 0.01 mM BW 284 C 51. All sections were then rinsed
with gentle agitation for 30 min in dH2O and placed in
0.1% cobalt chloride in water for 10 min. After further rins-
ing in dH2O, sections were placed in PB containing
1.39 mM 3,30-diaminobenzidine tetrahydrochloride
(DAB). After 5 min in the DAB solution, 50 ll of 0.15%
H2O2 in dH2O was added per ml of DAB solution, and
the reaction was carried out for approximately 3 min.
Sections were then washed in 0.01 M acetate buﬀer (pH
3.3), mounted on slides, coverslipped, and examined with
brightﬁeld microscopy.
For AChE staining, the sections were incubated in 4%
formaldehyde for approximately 10 h. The remainingprocedure was as described above for BChE except the
substrate was acetylthiocholine iodide at a concentration
of 0.4 mM and BuChE activity was inhibited with
0.06 mM ethopropazine. The sections were incubated
with the substrate for approximately 1 h.
Control experiments for cholinesterase histochemistry
were as described previously (Darvesh et al., 2012).Ab immunohistochemistry
Ab plaque load, comprising both non-ﬁbrillar and ﬁbrillar,
was visualized using immunohistochemistry for the Ab
protein. Brieﬂy, sections were rinsed for 30 min in PB
pH 7.4, for 16 h in 4% formaldehyde, 30 min in PB pH
7.4, 5 min in 0.05 M PB, followed by distilled water
(dH2O), and then gently shaken in 90% formic acid for
2 min for antigen retrieval. Sections were rinsed 5 times
in dH2O for 1 min each and 2 times in PB for 15 min.
Sections were then placed in 0.3% H2O2 in PB for
30 min to quench endogenous peroxidase activity and
rinsed again for 30 min in PB. Sections were then
incubated in PB containing 0.1% Triton X-100, normal
goat serum (1:100), and a polyclonal rabbit anti-Ab
antibody (1:400; 71–5800, Invitrogen, Camarillo, CA,
USA), speciﬁc for the 4- to 5-kDa amyloid peptide, for
approximately 16 h at room temperature. After rinsing in
PB, sections were incubated in PB with 0.1% Triton X-
100, biotinylated goat anti-rabbit secondary antibody
(1:500), and normal goat serum (1:1000) for 1 h. After
another rinse in PB, sections were placed in PB with
0.1% Triton X-100 and Vectastain Elite ABC kit (1:182;
PK-6100, Vector Laboratories, Burlingame, CA, USA),
according to the manufacturer’s speciﬁcations, for 1 h.
Sections were rinsed and developed in a solution of PB
containing 1.39 mM DAB. After 5 min, 50 ll of 0.3%
H2O2 in dH2O was added per mL of DAB solution, and
the sections were incubated for 5 min. The reaction was
stopped by rinsing the sections in 0.01 M acetate buﬀer
(pH 3.3). Sections were mounted onto glass slides, air-
dried, and coverslipped. In control experiments, no
staining was observed when Ab immunohistochemistry
was done on brain tissue from wild-type mice.Th-S histochemistry
Sections were rinsed in 0.05 M Tris-buﬀered saline pH 7.6
for 30 min, mounted onto glass slides, air-dried overnight,
rehydrated in dH2O, dehydrated in a series of ethanol
washes, cleared in xylene and rinsed in 50% ethanol.
Sections were then incubated overnight in a solution of
0.05% Th-S (Sigma–Aldrich, St. Louis, MO, USA) in
50% ethanol, rinsed in 80% aqueous ethanol and dH2O
and coverslipped with an aqueous mounting medium.Data analysis
The stained mouse brain sections were analyzed and
photographed using a Zeiss Axioplan 2 motorized
microscope with a Zeiss Axiocam HRc digital camera
using AxioVision 4.6 software (Carl Zeiss Canada Ltd.,
Toronto, Ontario, Canada). The photographs were
assembled using Adobe Photoshop (CS 5 version 12.0).
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background from diﬀerent images. Each mouse was
encoded with a random number to remove potential bias
while measuring plaque load. Plaque loads were
quantiﬁed using National Institutes of Health ImageJ
1.49d software and recorded as a percentage of the total
area, as described elsewhere (Darvesh et al., 2012).
Brieﬂy, gray-scale images of sections stained for BChE
activity, Ab and Th-S were taken throughout the brain. An
intensity threshold level was set such that stained plaques,
but not background, was selected. The cortex was outlined
with the polygon selection tool and measured for the per-
cent area covered by plaque staining. On average, eight
Ab sections, twelve Th-S-stained sections and four
BChE-stained sections were quantiﬁed per brain. For each
mouse, data from each section were summed to give a cor-
tical area and the total plaque area measured. This was
used to determine the percent plaque load for eachmouse.
Within each strain, sex and age group, the percent area
covered by plaque pathology was averaged. A two-tailed
Mann–Whitney non-parametric statistical test was applied
to determine the diﬀerence between means in the areas
covered by Ab pathology in 5XFAD and 5XFAD/BChE-
KO mice using Graphpad Prism (version 5.1 Windows).
Male and female mice were analyzed separately. Results
were considered signiﬁcantwhen the p-valuewas less than
the 5% critical level (p< 0.05).RESULTS
This work was undertaken to examine the eﬀect of BChE
on the accumulation of Ab plaques in the brain. The
5XFAD mouse model was chosen for this study since it
rapidly accumulates Ab pathology, beginning before
2 months of age (Oakley et al., 2006). The 5XFAD
mouse, which normally produces BChE, was crossed with
a BChE-knockout strain (BChE-KO) to generate a new
strain (5XFAD/BChE-KO) that still accumulates Ab pla-
ques but cannot synthesize BChE. To explore the eﬀect
of BChE on Ab accumulation over time, brain tissues from
5XFAD and 5XFAD/BChE-KO mice at 3 and 6 months of
age were stained and analyzed for Ab, ﬁbrillar Ab and
BChE activity associated with plaques. Female and male
mice were analyzed separately for pathology because it
had been observed earlier in human AD (Corder et al.,
2004; Barnes et al., 2005; Vest and Pike, 2013; Li and
Singh, 2014; Mielke et al., 2014) and in the 5XFAD mouse
model (Oakley et al., 2006) that females have higher pla-
que burden. Comparison of 5XFAD with 5XFAD/BChE-
KO mice should provide insights into possible role(s) of
BChE in Ab accumulation.Comparison of immunostained Ab, ﬁbrillar Ab and
BChE plaque accumulation in 5XFAD mice
As has been shown previously (Oakley et al., 2006), the
5XFAD mouse accumulates Ab plaques (Fig. 1A, B). In
addition, as seen in human AD (Mesulam and Geula,
1994; Geula and Mesulam, 1995; Guillozet et al., 1997)
and the 2XFAD mouse model (Darvesh et al., 2012),
BChE activity was associated with many of these plaques(Fig. 1C). There was no AChE activity visualized with cor-
tical Ab plaques in the 5XFAD mice (Fig. 1D).
The plaque pathology for female and male 5XFAD
mice at 3 and 6 months of age was visualized as
illustrated in Fig. 2. The plaque burden was quantiﬁed,
expressed as a percentage of cerebral cortical area
covered by pathology and averaged for each sex and
age group (Fig. 3). The immunostained Ab, ﬁbrillar Ab
and BChE-associated plaque loads for female and male
mice were shown to accumulate early, by 3 months of
age, and increased with age. The area of the cerebral
cortex covered by plaques stained with Th-S or BChE
histochemistry was less than that by Ab immunostaining
(Fig. 3). Female mice showed increased Ab plaque
burden compared to males, which was a trend at
3 months and signiﬁcantly higher at 6 months
(p= 0.0173). In addition, the ﬁbrillar Ab plaque burden
was signiﬁcantly higher in females relative to males at
both 3 months (p= 0.0229) and 6 months (p= 0.0043).
Similarly, females had higher BChE-associated plaque
burden compared to males (p= 0.0164) at 3 months, a
trend which continued at 6 months (p= 0.0519).
Generation and characterization of the 5XFAD/BChE-
KO mouse
To explore whether the presence of BChE modulates Ab
deposition, a new strain of mouse was produced by
breeding 5XFAD mice with a BChE-KO strain to
generate the 5XFAD/BChE-KO strain. Comparison of
the PCR products for APP, PSEN1 and BChE
genotypes for various strains used in this study is
shown in Fig. 4. This indicates the absence of BChE
gene in the newly generated 5XFAD/BChE-KO mouse.
The 5XFAD/BChE-KO mice are viable, fertile, eat
appropriately, do not exhibit any overt phenotypic
diﬀerences compared to the 5XFAD strain and do not
produce BChE. Comparative cholinesterase staining in
5XFAD and 5XFAD/BChE-KO brains (Fig. 5) conﬁrmed
BChE plaque staining in the cerebral cortex of the 5XFAD
mouse but no BChE staining in any brain structures of the
5XFAD/BChE-KO strain. No diﬀerences in AChE staining
were observed in the two strains.
Comparison of immunostained Ab and ﬁbrillar Ab
plaque accumulation in 5XFAD/BChE-KO Mice
The 5XFAD/BChE-KO mice, like the 5XFAD strain
(Fig. 3), were found to accumulate Ab plaques in the
cerebral cortex, to show increased plaque
immunostaining over time and to exhibit a greater
burden of plaque pathology in females than males
(Fig. 6). Compared to male mice, female 5XFAD/BChE-
KO mice had signiﬁcantly more Ab plaque
immunostaining at both 3 months (p= 0.028) and at
6 months (0.0095). The same was true for ﬁbrillar Ab at
3 (p= 0.003) and 6 (p= 0.0095) months of age.
Eﬀect of lack of BChE on Ab plaque immunostaining
In female mice, at 3 months, the 5XFAD/BChE-KO can be
seen to have a lower immunostained Ab plaque burden
relative to the 5XFAD mice (Fig. 7) but the diﬀerence
Fig. 1. Photomicrographs showing staining in a 6-month-old male 5XFAD mouse for Ab using immunohistochemistry (A), ﬁbrillar Ab using
thioﬂavin-S histoﬂuorescence (B) and histochemical staining for butyrylcholinesterase (C) and acetylcholinesterase (D). Scale bar = 100 lm. Note
BChE staining but not AChE staining of cortical plaques.
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females was the same in these two strains of mice.
Overall, the absence of BChE did not have any
signiﬁcant eﬀect on Ab plaques in female mice (Fig. 8).
In male mice, on the other hand, the 5XFAD/BChE-KO
mice appeared to have lower immunostained Ab
plaques at 3 and 6 months, as illustrated in Figs. 7 and
8. This suggests that the absence of BChE has more
eﬀect in lowering Ab immunostaining in male mice than
in females.Eﬀect of lack of BChE on ﬁbrillar Ab
In female mice, at 3 and 6 months, the 5XFAD/BChE-KO
can be seen to have lower ﬁbrillar Ab compared to 5XFAD
(Fig. 9), but the diﬀerence was not statistically signiﬁcant
(Fig. 10). On the other hand, in male 5XFAD/BChE-KO
mice, there was signiﬁcantly less ﬁbrillar Ab
accumulation at both 3 (p= 0.0247) and 6 (p= 0.0159)
months of age compared to 5XFAD mice.
In summary, comparison of the ﬁbrillar Ab plaque
burden in 5XFAD and 5XFAD/BChE-KO mice (Table 2)
indicates that, in the absence of BChE, there is less
pathology at the same time points, especially for male
mice. The area covered by Th-S stained plaques in
male 5XFAD/BChE-KO mice was 62% and 69% less
than male 5XFAD mice at 3 and 6 months, respectively.In female 5XFAD/BChE KO mice, compared to 5XFAD
mice, the Th-S plaque load in the cerebral cortex was
observed (Table 2) to be diminished by 17% and 22%
at 3 and 6 months, respectively.DISCUSSION
Butyrylcholinesterase (BChE) is an enzyme that becomes
associated with Ab plaques that are characteristic of AD
(Mesulam and Geula, 1994) and in mouse models of
AD such as the 2XFAD mouse (Darvesh et al., 2012)
and the 5XFAD strain used in this study (Figs. 1–3).
The reason for the interaction between Ab and BChE is
uncertain but it is known that the presence of BChE in
Ab plaques alters the catalytic activity of this enzyme, pro-
ducing altered pH optimum and sensitivity to cholinester-
ase inhibitors (Geula and Mesulam, 1989). Conversely, it
has been indicated that Ab is also aﬀected in this interac-
tion, being transformed from a ‘‘benign’’ form to a ‘‘malig-
nant’’ ﬁbrillar form (Guillozet et al., 1997). Development of
the mouse model (5XFAD/BChE-KO) that does not pro-
duce BChE (Figs. 4–6), and comparison of the levels of
pathology with the 5XFAD strain that does produce
BChE (Figs. 7–10) has provided some insights into the
eﬀect BChE has on the accumulation of Ab pathology.
Staining for Ab by immunohistochemistry provides a
measure of Ab plaque burden in the cerebral cortex.
Fig. 2. Photomicrographs exemplifying plaque staining for Ab, ﬁbrillar Ab (Th-S) and butyrylcholinesterase (BChE) enzyme activity in female and
male 5XFAD mice at 3 and 6 months of age. Note the similarity in distribution and plaque burden stained for BChE and ﬁbrillar Ab (Th-S). Scale
bar = 250 lm.
Fig. 3. Bar graphs of the percentage of cerebral cortex area covered with plaques in 5XFAD mice at 3 and 6 months of age stained for
butyrylcholinesterase (BChE) enzyme activity, ﬁbrillar Ab (Th-S) and Ab immunostaining presented as mean ± SEM.
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(20–25%) of these Ab plaques are ﬁbrillar. BChE also
stains a similarly small proportion of the Ab plaque load
(Fig. 3) suggesting that BChE also stains a selective
pool of AD plaques. It has been shown that BChE is
associated with ﬁbrillar Ab in human AD (Guillozet et al.,
1997) implying that BChE in the 5XFAD cerebral cortex
may also be associated with ﬁbrillar Ab.In the 5XFAD/BChE-KO mice, there is a signiﬁcant
reduction (nearly 70% in males and 20% in females)
of ﬁbrillar Ab (Fig. 10, Table 2). This decrease in ﬁbrillar
Ab in 5XFAD/BChE-KO mice supports the previous
suggestion (Guillozet et al., 1997) that BChE may be
involved in the development of ﬁbrillar Ab.
It is evident in both 5XFAD and 5XFAD/BChE-KO
strains examined here that females accumulate more
Fig. 4. Photograph of an agarose gel of the PCR gene products for APP, PSEN1 and BChE from: (A) 5XFAD; (B) 5XFAD/BChE-het; (C) 5XFAD/
BChE-KO; (D) BChE-WT; (E) BChE-KO. Note, in the 5XFAD/BChE-het mouse, upper band represents PCR product of BChE gene, lower band is
that for the neomycin reporter gene that replaced the BChE gene. In 5XFAD/BCHE-KO strain, upper (BChE) band is absent.
Fig. 5. Staining for butyrylcholinesterase (BChE) and acetylcholinesterase (AChE) enzyme activity in 6-month male 5XFAD and 5XFAD/BChE-KO
mice. The 5XFAD mouse has BChE associated with Ab plaques. There is no BChE staining in the 5XFAD/BChE-KO mouse. There is no AChE
staining of plaques in the cerebral cortex of either strain. Scale bar = 0.5 mm.
Fig. 6. Bar graphs of the percentage of cerebral cortex area in 5XFAD/BChE-KO mice covered with plaque stained for ﬁbrillar Ab (Th-S) and Ab
immunostaining presented as mean ± SEM.
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Fig. 7. Photomicrographs showing Ab immunostaining in female and male 5XFAD and 5XFAD/BChE-KO mice at 3 and 6 months of age. Scale
bar = 200 lm.
Fig. 8. Bar graphs indicate percentage of the cerebral cortex area covered with Ab immunostaining presented as mean ± SEM. A two-tailed
Mann–Whitney non-parametric statistical test was applied to determine the diﬀerence between means in the areas covered by Ab pathology in
5XFAD and 5XFAD/BChE-KO mice.
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shown in mouse models of AD (Oakley et al., 2006;
Hirata-Fukae et al., 2008; Carroll et al., 2010) and in
human studies (Henderson and Buckwalter, 1994;
Corder et al., 2004; Barnes et al., 2005; Sinforiani et al.,
2010; Vest and Pike, 2013; Li and Singh, 2014; Mielke
et al., 2014). Some studies have reported more women
than men have AD (Seshadri et al., 1997; Plassman
et al., 2007; Irvine et al., 2012; Mielke et al., 2014), but
this diﬀerence has often been attributed to the fact that
women live longer than men (Alzheimer’s Association,
2014). However, an analysis of eight population-based
studies, with 2 years of observation, indicated that in ﬁve
of these studies there was a greater risk of AD in females,
while in three of the studies no diﬀerence was observed
(Barnes et al., 2005). On the other hand, a number of
studies have demonstrated higher plaque pathology that
is attendant with a greater cognitive decline in women(Henderson and Buckwalter, 1994; Corder et al., 2004;
Barnes et al., 2005; Sinforiani et al., 2010; Vest and
Pike, 2013; Li and Singh, 2014; Mielke et al., 2014).
These observations have been recapitulated in a number
of animal models of AD that have demonstrated greater
behavioral deﬁcits and AD pathology in females (Oakley
et al., 2006; Hirata-Fukae et al., 2008; Carroll et al.,
2010). In addition, higher BChE levels have been
observed in females than in males (Mundell, 1944;
Illsley and Lamartiniere, 1981; Edwards and Brimijoin,
1983; Alves-Amaral et al., 2010). Furthermore, BChE
levels in rat serum were observed to be three times higher
in females than males, and that gonadectomy in both
sexes abolished this diﬀerence. Androgen and estrogen
replacement of gonadectomised animals reversed this
eﬀect, extending previous work that androgens and estro-
gens modulate synthesis of BChE (Illsley and
Lamartiniere, 1981). Since sex hormones appear to
Fig. 9. Photomicrographs exemplifying thioﬂavin-S staining in female and male 5XFAD and 5XFAD/BChE-KO mice. Scale bar = 200 lm.
Fig. 10. Bar graphs indicate percentage of the cerebral cortex area covered with ﬁbrillar Ab pathology presented as mean ± SEM. A two-tailed
Mann–Whitney non-parametric statistical test was applied to determine the diﬀerence between means in the areas covered by Ab pathology in
5XFAD and 5XFAD/BChE-KO mice. *p< 0.05.
Table 2. Percent area of the cerebral cortex covered with Ab plaques visualized using immunohistochemistry and ﬁbrillar Ab visualized with thioﬂavin-S,
presented as mean ± SEM
3 Months 6 Months
Immunostained Ab Fibrillar Ab Immunostained Ab Fibrillar Ab
Female mice
5XFAD 5.32 ± 2.01 1.11 ± 0.35 16.85 ± 3.11 4.88 ± 1.19
5XFAD/BChE-KO 3.72 ± 2.26 0.92 ± 0.41 16.97 ± 2.98 3.79 ± 0.53
Male mice
5XFAD 3.08 ± 2.25 0.6 ± 0.29 10.01 ± 3.53 2.76 ± 0.66
5XFAD/BChE-KO 1.26 ± 0.77 0.23 ± 0.17 5.44 ± 2.14 0.85 ± 0.27
432 G. A. Reid, S. Darvesh /Neuroscience 298 (2015) 424–435modulate both Ab deposition and BChE levels, the ques-
tion that arises is how these three factors interact in AD
pathogenesis.
Since the seminal work of Baulieu and Robel (1990), it
is established that the brain synthesizes its own sexsteroid hormones (neurosteroids). All the enzymes for
the synthesis of neurosteriods are found in certain popu-
lations of neurons and glia (Hojo et al., 2004). There is
growing evidence that brain estrogens modulate brain
development and behavior (Stanic´ et al., 2014), help
G. A. Reid, S. Darvesh /Neuroscience 298 (2015) 424–435 433regulate cholinergic, serotonergic and dopaminergic
transmitter subtypes (Do Rego et al., 2009; Gibbs,
2010), protect against age-related atrophy of the hip-
pocampus (Eberling et al., 2003) and enhance outgrowth
and survival of neurons in culture (Brinton et al., 1997).
Testosterone and progesterone have also been shown
to stimulate neurite growth, protect against neuronal
death and enhance memory (Malsbury and McKay,
1994; Carroll et al., 2007; Rosario et al., 2010).
Testosterone has also been shown to promote non-amy-
loidogenic processing of amyloid precursor protein
(Gouras et al., 2000).
Earlier investigations (Xing et al., 2013) have shown
that estrogen inﬂuences BCHE gene expression and func-
tion while other work (Gibbs, 1994) indicated a gene–gene
interaction between BCHE gene and estrogen-associated
genes. For example, it has been shown that certain genetic
polymorphisms in the P450C19 aromatase gene and in the
estrogen receptor-a gene increase the risk of AD
(Comborros et al., 2005, 2007). However, in women with
BChE-K polymorphism, where there is 30% less BChE
(Bartels et al., 1992), the increased risk of AD due to
P450C19 aromatase or estrogen receptor-a genetic poly-
morphisms is overcome, suggesting that lower BChE
levels are protective. Also, a recent genome-wide associa-
tion study, using 18F ﬂorbetapir Ab PET imaging in 555
patients in the Alzheimer Disease Neuroimaging Initiative
study has demonstrated that the BChE gene is one of the
few genes identiﬁed, along with that for ApoE, that is asso-
ciatedwith AD (Ramananet al., 2014). This study found the
largest known eﬀect of the BChE gene on AD-related phe-
notype and concluded that BChE-associated AD neu-
ropathology, and genetic variation at the BCHE locus
associated with Ab burden, may provide a means for
BChE-modulating agents to alter disease progression
(Ramanan et al., 2014).CONCLUSION
BChE is consistently associated with AD pathology
including in the 5XFAD mouse model. Diminished
ﬁbrillar Ab plaque deposition in the absence of BChE,
particularly in males, suggests that this enzyme
promotes Ab plaque pathology. Further comparative
studies with 5XFAD and 5XFAD/BChE-KO, in both
males and females, should help elucidate a mechanism
for BChE-related promotion of ﬁbrillar Ab plaques and
provide a model for directly testing potential disease-
modifying therapeutics for AD.
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